BSE filing, NSE: RBLBANK. Summary written from the filing by ALFA Finder's alert engine.
RBL Bank Ltd: key numbers
- Share price
- ₹349.95
- Market cap
- ₹54,322 Cr
- Revenue (annual)
- ₹14,337 Cr
- Net profit (annual)
- ₹879.0 Cr
- P/E (TTM)
- 45.1×Sector 19.7×
- Promoter holding
- 59.88%-0.12% QoQ
- FII holding
- 8.70%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from RBL Bank Ltd
All →RBL Bank Annual General Meeting
RBL Bank seeks shareholder approval via postal ballot for remuneration of its MD & CEO, an Executive Director and a retired ED. Voting runs October 28 to November 26, 2026.
RBL Bank Employee Stock Options
RBL Bank allotted 5,28,745 ESOP shares to employees following exercise of vested options on October 26, 2026. Paid-up capital rose to 155.28 crore shares.
RBL Bank Regulatory Approval
RBL Bank has received RBI approval for the amalgamation of Emirates NBD Bank's Indian branches. The integration is effective from December 01, 2026.
RBL Bank Earnings Call Transcript: Key Takeaways
Strong balance sheet expansion driven by one-time FCNR(B) deposits and equity capital.
RBL Bank Management Change
RBL Bank announced the appointment of Mr. Ashwini Kumar Choudhary as Chief Risk Officer and the re-appointment of Mr. Prakash Gupta as Chief Compliance Officer.
RBL Bank Investor Presentation: Key Takeaways
RBL Bank reports strong Q2 FY27 performance with Net Profit surging 170% YoY to ₹4.82 bn. Growth driven by 37% NII expansion and significant improvement in asset quality.
Other regulatory approval announcements
All →Shalby Regulatory Approval
Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.
Elantas Beck India Regulatory Approval
Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.
Kalyani Cast-Tech Regulatory Approval
Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.
Mukka Proteins Regulatory Approval
Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.
- Execution
- October 1, 2026 to December 31, 2027
Canara Bank Regulatory Approval
Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.
- Value
- ₹1,500 Cr
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.